|
1
|
Ferté C, André F and Soria JC: Molecular
circuits of solid tumors: prognostic and predictive tools for
bedside use. Nat Rev Clin Oncol. 7:367–380. 2010.PubMed/NCBI
|
|
2
|
Sun CH, Chang YH and Pan CC: Activation of
the PI3K/Akt/mTOR pathway correlates with tumour progression and
reduced survival in patients with urothelial carcinoma of the
urinary bladder. Histopathology. 58:1054–1063. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mazzoletti M, Bortolin F, Brunelli L,
Pastorelli R, Di Giandomenico S, Erba E, Ubezio P and Broggini M:
Combination of PI3K/mTOR inhibitors: antitumor activity and
molecular correlates. Cancer Res. 71:4573–4584. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen Y, Wang BC and Xiao Y: PI3K: A
potential therapeutic target for cancer. J Cell Physiol.
227:2818–2821. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ghayad SE and Cohen PA: Inhibitors of the
PI3K/Akt/mTOR pathway: new hope for breast cancer patients. Recent
Pat Anticancer Drug Discov. 5:29–57. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liu W, Zhou Y, Reske SN and Shen C: PTEN
mutation: many birds with one stone in tumorigenesis. Anticancer
Res. 28:3613–3619. 2008.PubMed/NCBI
|
|
7
|
Heikkinen T, Greco D, Pelttari LM,
Tommiska J, Vahteristo P, Heikkila P, Blomqvist C, Aittomaki K and
Nevanlinna H: Variants on the promoter region of PTEN affect breast
cancer progression and patient survival. Breast Cancer Res.
13:R1302011. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Carraway H and Hidalgo M: New targets for
therapy in breast cancer: mammalian target of rapamycin (mTOR)
antagonists. Breast Cancer Res. 6:219–224. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lai JP, Sandhu DS, Yu C, Moser CD, Hu C,
Shire AM, Aderca I, Murphy LM, Adjei AA, Sanderson S and Roberts
LR: Sulfatase 2 protects hepatocellular carcinoma cells against
apoptosis induced by the PI3K inhibitor LY294002 and ERK and JNK
kinase inhibitors. Liver Int. 30:1522–1528. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shin JY, Kim JO, Lee SK, Chae HS and Kang
JH: LY294002 may overcome 5-FU resistance via down-regulation of
activated p-AKT in Epstein-Barr virus-positive gastric cancer
cells. BMC Cancer. 13:4252010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fujiwara M, Izuishi K, Sano T, Hossain MA,
Kimura S, Masaki T and Suzuki Y: Modulating effect of the
PI3-kinase inhibitor LY294002 on cisplatin in human pancreatic
cancer cells. J Exp Clin Cancer Res. 27:76–84. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yang S, Xiao X, Meng X and Leslie KK: A
mechanism for synergy with combined mTOR and PI3 kinase inhibitors.
PLoS One. 6:e263432011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Morelli MP, Tentler JJ, Kulikowski GN, Tan
AC, Bradshaw-Pierce EL, Pitts TM, Brown AM, Nallapareddy S,
Arcaroli JJ, Serkova NJ, et al: Preclinical activity of the
rational combination of Selumetinib (AZD6244) in combination with
Vorinostat in KRAS mutant colorectal cancer models. Clin Cancer
Res. 18:1051–1062. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sun HW, Wu C, Tan HY and Wang QS:
Combination DLL4 with Jagged1-siRNA can enhance inhibition of the
proliferation and invasiveness activity of human gastric carcinoma
by Notch1/VEGF pathway. Hepatogastroenterology. 59:115–116.
2011.PubMed/NCBI
|
|
15
|
Adamo B, Deal AM, Burrows E, Geradts J,
Hamilton E, Blackwell KL, Livasy C, Fritchie K, Prat A, Harrell JC,
et al: Phosphatidylinositol 3-kinase (PI3K) pathway activation in
breast cancer brain metastases. Breast Cancer Res. 13:R1252011.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Miller TW, Rexer BN, Garrett JT and
Arteaga CL: Mutations in the phosphatidylinositol 3-kinase pathway:
role in tumor progression and therapeutic implications in breast
cancer. Breast Cancer Res. 13:2242011. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dozza B, Smith MA, Perry G, Tabaton M and
Strocchi P: Regulation of glycogen synthase kinase-3beta by
products of lipid peroxidation in human neuroblastoma cells. J
Neurochem. 89:1224–1232. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Damsky WE, Curley DP, Santhanakrishnan M,
Rosenbaum LE, Platt JT, Gould Rothberg BE, Taketo MM, Dankort D,
Rimm DL, McMahon M and Bosenberg M: β-catenin signaling controls
metastasis in Braf-activated Pten-deficient melanomas. Cancer Cell.
20:741–754. 2011.
|
|
19
|
Zhang X, Chen T, Zhang J, Mao Q, Li S,
Xiong W, Qiu Y, Xie Q and Ge J: Notch1 promotes glioma cell
migration and invasion by stimulating β-catenin and NF-κB signaling
via AKT activation. Cancer Sci. 103:181–190. 2011.PubMed/NCBI
|
|
20
|
Perry JM, He XC, Sugimura R, Grindley JC,
Haug JS, Ding S and Li L: Cooperation between both Wnt/β-catenin
and PTEN/PI3K/Akt signaling promotes primitive hematopoietic stem
cell self-renewal and expansion. Genes Dev. 25:1928–1942. 2011.
|
